Emerging PCSK9 inhibitors for treating dyslipidaemia: buttressing the gaps in coronary prevention

Area of Science:

• Cardiovascular Medicine
• Pharmacology

Background:

• Atherosclerotic cardiovascular disease (ACVD) is a leading global cause of death.
• High low-density lipoprotein-cholesterol (LDL-C) levels significantly contribute to ACVD.
• Statins are primary cholesterol-lowering therapies, but additional options are needed.

Purpose of the Study:

• To discuss the medical need for novel cholesterol-lowering treatments.
• To review the scientific rationale for proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors.
• To outline the current therapeutic status of PCSK9 inhibitors.

Main Methods:

• Literature review on ACVD, LDL-C, and PCSK9 inhibitors.
• Discussion of clinical evidence and ongoing trials for PCSK9 inhibitors.
• Analysis of PCSK9 inhibition mechanisms and therapeutic applications.

Main Results:

• PCSK9 inhibitors represent a new class of cholesterol-lowering drugs.
• These inhibitors are particularly beneficial for patients with familial hypercholesterolaemia (FH) and statin intolerance.
• Elevated lipoprotein(a) (Lp(a)) levels may also respond to PCSK9 inhibition.

Conclusions:

• Anti-PCSK9 monoclonal antibodies (mAbs) are a promising therapy for managing high cholesterol.
• PCSK9 inhibitors offer hope for patients with FH, statin intolerance, and elevated Lp(a).
• Further clinical trials are investigating the efficacy of PCSK9 inhibitors in reducing cardiovascular events in high-risk populations.